One Spray per Device, Without the Need for Priming, Provides Greater Ease of Use The new Nascobal ® Nasal Spray single-use device requires no assembly and simplifies the tracking of dose ...

Par announced the launch of Nascobal (cyanocobalamin) Nasal Spray in a single-use device for the maintenance of normal hematologic status in pernicious anemia patients who are in remission following ...

WOODCLIFF LAKE, N.J., June 10, 2014 /PRNewswire/ --Strativa Pharmaceuticals, the branded division of Par Pharmaceutical Companies, Inc., today announced that the U.S. Food and Drug Administration has ...

Feb. 3, 2005 — The U.S. Food and Drug Administration (FDA) has approved a nasal spray formulation of cyanocobalamin for the treatment of vitamin B 12 deficiency; a new indication for orphan drug PTC ...

Kumar was in Chennai on Thursday to announce opening of regional reference laboratory in the city. Global pharma major Lupin Limited on Monday announced that it has received approval from the United ...

Strativa announced that the FDA has approved Nascobal (cyanocobalamin) Nasal Spray in a single-use device for the maintenance of normal hematologic status in pernicious anemia patients who are in ...

Global pharma major Lupin Limited (Lupin) announced the launch of the United States Food and Drug Administration (FDA) approved cyanocobalamin nasal spray, 500 mcg/spray (one spray per device).

Indian pharmaceutical firm Lupin on July 3 said it received approval from the United States Food and Drug Administration (US FDA) for its Cyanocobalamin nasal spray, used in maintaining normal vitamin ...

Lupin’s stock rose more than 1% in early trade on July 4 after the company received approval from the US Food and Drug Administration (USFDA) for nasal spray. At around 11.53 AM, Lupin was trading at ...